Markus Galanski


Affiliation: University of Vienna
Country: Austria


  1. request reprint
    Galanski M, Keppler B. Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med Chem. 2007;7:55-73 pubmed
  2. Höfer D, Varbanov H, Legin A, Jakupec M, Roller A, Galanski M, et al. Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy. J Inorg Biochem. 2015;153:259-271 pubmed publisher
  3. request reprint
    Galanski M, Slaby S, Jakupec M, Keppler B. Synthesis, characterization, and in vitro antitumor activity of osteotropic diam(m)ineplatinum(II) complexes bearing a N,N-bis(phosphonomethyl)glycine ligand. J Med Chem. 2003;46:4946-51 pubmed
    ..Within the series of complexes under investigation, potency decreases depending on the coordinated amine ligand in the following order: trans-R,R-chxn > trans-S,S-chxn > NH(3) > or = cis-R,S-chxn > en...
  4. request reprint
    Galanski M, Jakupec M, Keppler B. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem. 2005;12:2075-94 pubmed
    ..It focuses also on innovative synthetic strategies leading to novel classes of platinum complexes. A small part of the review is dedicated to new analytical approaches which have been supplied to or emerged in this field of research...
  5. Höfer D, Varbanov H, Hejl M, Jakupec M, Roller A, Galanski M, et al. Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes. J Inorg Biochem. 2017;174:119-129 pubmed publisher